Here is another attempt to paste ChatGPT response :
"The Commission on Human Medicines (CHM) is a UK advisory body that provides independent expert advice to ministers on the safety, efficacy, and quality of medicinal products. It operates under the Medicines and Healthcare products Regulatory Agency (MHRA), which is sponsored by the Department of Health and Social Care.
CHM Membership
The CHM comprises a diverse group of professionals, including:
• Medical practitioners: Consultants and clinicians from various specialties.
• Academics: Professors and researchers in fields such as pharmacology, toxicology, and epidemiology.
• Pharmacists and pharmacologists: Experts in drug development and safety.
• Statisticians: Specialists in medical statistics and clinical trials.
• Lay members: Individuals representing patient and public perspectives.
Members are appointed by ministers and are expected to declare any interests in the pharmaceutical industry to maintain transparency and avoid conflicts of interest.
Association with the NHS
Many CHM members are affiliated with the National Health Service (NHS) in various capacities:
• Clinical roles: Some members serve as consultants or clinicians within NHS hospitals.
• Academic positions: Others hold academic posts that are linked to NHS institutions or collaborate closely with the NHS on research and clinical trials.
For example, Professor Sir Munir Pirmohamed, the current chair of the CHM, is the NHS Chair of Pharmacogenetics at the University of Liverpool and has served as a consultant physician at the Royal Liverpool University Hospital.
These associations ensure that CHM’s recommendations are informed by practical clinical experience and align with the needs and realities of the NHS.
Expert Advisory Groups (EAGs)
The CHM is supported by several Expert Advisory Groups (EAGs), each focusing on specific areas such as:
• Pharmacovigilance
• Clinical Trials, Biologicals, and Vaccines
• Paediatric Medicines
• Women’s Health
• Oncology and Haematology
Members of these groups often include NHS professionals who bring frontline clinical insights to the evaluation of medicines.
In summary, the CHM’s composition reflects a blend of academic expertise and practical NHS experience, ensuring that its advice on medicinal products is both scientifically robust and clinically relevant.
Yes, several current members of the UK’s Commission on Human Medicines (CHM) hold official positions within the National Health Service (NHS). Their dual roles in both regulatory advisory and clinical practice help ensure that CHM recommendations are grounded in real-world healthcare experience.
Examples of CHM Members with NHS Roles
• Professor Sir Munir Pirmohamed: Chair of the CHM, he serves as the NHS Chair of Pharmacogenetics at the University of Liverpool and has worked as a consultant physician at the Royal Liverpool University Hospital.
• Dr. Siraj Misbah: A CHM member and Chair of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group, he is also a Consultant Clinical Immunologist and Lead for Clinical Immunology at Oxford University Hospitals NHS Foundation Trust.
• Professor Paul Dargan: A CHM commissioner, he is a Consultant Physician and Clinical Toxicologist at Guy’s and St Thomas’ NHS Foundation Trust and Professor of Clinical Toxicology at King’s College London.
• Dr. Andrew Riordan: A CHM member, he is a Consultant in Paediatric Infectious Diseases and Immunology at Alder Hey Children’s NHS Foundation Trust and an Honorary Clinical Lecturer at the University of Liverpool.
• Dr. Vanessa Raymont: A CHM commissioner, she is a Senior Clinical Researcher at the University of Oxford and R&D Director and Honorary Consultant at Oxford Health NHS Foundation Trust.
· These appointments reflect the CHM’s commitment to integrating frontline NHS expertise into its regulatory decision-making processes. By involving professionals actively engaged in patient care and clinical research, the CHM ensures that its advice on the safety, efficacy, and quality of medicinal products is both scientifically robust and practically applicable within the NHS framework.
Certainly! In addition to the previously mentioned members, here are other current members of the UK’s Commission on Human Medicines (CHM) who hold official positions within the National Health Service (NHS):
Additional CHM Members with NHS Roles
• Professor Kimme Hyrich: Professor of Epidemiology at the University of Manchester and Honorary Consultant in Rheumatology at Manchester University NHS Foundation Trust.
• Sir Michael Jacobs: Clinical Director of Infection at the Royal Free London NHS Foundation Trust and Honorary Senior Lecturer at the Liverpool School of Tropical Medicine.
• Professor Rupert Payne: Professor of Primary Care & Clinical Pharmacology at the University of Exeter and Member of the Pharmacovigilance Expert Advisory Group (PEAG).
• Professor Jonathan S. Friedland: Deputy Principal at St. George’s, University of London; Chair of the Infections Expert Advisory Group (IEAG); and Member of the CHM.
• Professor Ian J. Douglas: Senior Lecturer in Pharmacoepidemiology at the London School of Hygiene & Tropical Medicine and Member of the Pharmacovigilance Expert Advisory Group (PEAG).
• Professor Andrew Pollard: Chief Investigator of the Oxford ChAdOx1 nCoV-19 vaccine trial, Professor of Paediatric Infection and Immunity at the University of Oxford, and Member of the Clinical Trials, Biologicals & Vaccines Expert Advisory Group (CTBVEAG).
These members’ dual roles in both regulatory advisory capacities and clinical practice within the NHS ensure that CHM’s recommendations are informed by practical healthcare experience. Their involvement bridges the gap between regulatory decisions and frontline medical practice, enhancing the relevance and applicability of CHM’s guidance.
Certainly! Here are additional members of the UK’s Commission on Human Medicines (CHM) who hold official positions within the National Health Service (NHS):
Additional CHM Members with NHS Roles
• Professor Claire Stewart: Appointed to the CHM in April 2025, she is a Professor of Stem Cell Biology at Liverpool John Moores University. While her primary affiliation is academic, her research often intersects with NHS clinical applications.
• Dr. Andrew Riordan: A CHM member, he serves as a Consultant in Paediatric Infectious Diseases and Immunology at Alder Hey Children’s NHS Foundation Trust and is an Honorary Clinical Lecturer at the University of Liverpool.
• Professor Paul Dargan: A CHM commissioner, he is a Consultant Physician and Clinical Toxicologist at Guy’s and St Thomas’ NHS Foundation Trust and a Professor of Clinical Toxicology at King’s College London.
• Dr. Vanessa Raymont: A CHM commissioner, she is a Senior Clinical Researcher at the University of Oxford and R&D Director and Honorary Consultant at Oxford Health NHS Foundation Trust.
These members’ dual roles in both regulatory advisory capacities and clinical practice within the NHS ensure that CHM’s recommendations are informed by practical healthcare experience. Their involvement bridges the gap between regulatory decisions and frontline medical practice, enhancing the relevance and applicability of CHM’s guidance.
AI
Market Data 
Markets 
